SmartStop Self Storage REIT, Inc. Acquires Five Premium Self-Storage Facilities in the Houston Metropolitan Area
BUSINESS WIRE)--SmartStop Self Storage REIT, Inc. ('SmartStop') (NYSE: SMA), an internally managed real estate investment trust and a premier owner and operator of self-storage facilities in the United States and Canada, announced the acquisition of five Class A, high-quality self-storage properties strategically located throughout the Houston Metropolitan Statistical Area.
The newly acquired portfolio features a diverse mix of multi- and single-story facilities that collectively offer more than approximately 420,000 net rentable square feet and approximately 3,800 storage units, including climate-controlled units and RV spaces. Each facility is well-positioned within a high-demand submarket of Houston, benefiting from strong demographic profiles, high traffic visibility, and proximity to residential and retail development.
The newly acquired properties are located at:
2412 W Holcombe Blvd, Houston, Texas
21836 Holzwarth Rd, Spring, Texas
9040 Louetta Rd, Spring, Texas
32620 FM2978, Magnolia, Texas
18250 Interstate 45 S, Shenandoah, Texas
These facilities will serve a range of high-demand neighborhoods and communities, including West University Place, Braeswood Place, and the Texas Medical Center in central Houston; Gleannloch Farms, Spring Creek Oaks, and Old Town Spring in northern Spring; as well as affluent suburban areas such as The Woodlands, Shenandoah, Magnolia, and NorthGrove. Many of these communities have experienced sustained population growth, increasing the need for convenient, secure, and modern storage solutions.
'We commend Kathy and Scott Tautenhahn for developing a portfolio of such high-quality, well-located assets,' said Wayne Johnson, President and Chief Investment Officer of SmartStop. 'These properties exemplify the type of institutional-grade investments that align with our long-term strategy—targeting high-growth markets with strong demographics and enduring demand. We're also grateful to Aaron Swerdlin with Newmark for his active involvement throughout the entire transaction process.'
About SmartStop Self Storage REIT, Inc. (SmartStop):
SmartStop Self Storage REIT, Inc. ('SmartStop') (NYSE: SMA) is a self-managed REIT with a fully integrated operations team of more than 600 self-storage professionals focused on growing the SmartStop® Self Storage brand. SmartStop, through its indirect subsidiary SmartStop REIT Advisors, LLC, also sponsors other self-storage programs. As of June 17, 2025, SmartStop has an owned or managed portfolio of 227 operating properties in 23 states, the District of Columbia, and Canada, comprising approximately 162,700 units and 18.3 million rentable square feet. SmartStop and its affiliates own or manage 42 operating self-storage properties in Canada, which total approximately 35,700 units and 3.6 million rentable square feet. Additional information regarding SmartStop is available at www.smartstopselfstorage.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
If You'd Invested $5,000 in Kohl's Stock 3 Years Ago, Here's How Much You'd Have Today
Kohl's shares have vastly underperformed the overall market. The board of directors slashed the quarterly dividend this year. The department store chain faces challenges. 10 stocks we like better than Kohl's › Department store giant Kohl's (NYSE: KSS) stock performance over the last three years shows how important it is for investors to periodically assess a company's long-term prospects. You should also periodically check how a company is progressing to see if you should give up and instead invest in a stock with better prospects. If you made a $5,000 investment in Kohl's shares three years ago, you'd have a lot less money today. Kohl's stock price closed at $8.12 on June 13 compared to $40.54 three years ago. That works out to a stock-price loss of 80%. During this time, the S&P 500 index gained 60%. Investing $5,000 then means you would have purchased 123 shares in June 2022. Those shares have a value of about $1,000 today. You would have also collected dividends during those three years. These payments were $0.50 per share per quarter until the board of directors slashed the latest per-share payout to $0.125 (or $0.50 annually). That means you would have collected a little under $700 in dividends. That leaves you a paltry $1,700 in total return for your initial $5,000 investment. By contrast, investing that same amount in the S&P 500 index means you'd have nearly $8,400 today. When companies cut dividends, it's often a sign that things aren't going well for the company. That's the case with Kohl's. Kohl's, operating in the competitive retail industry, has continued to face challenges in growing its sales. In fact, same-store sales (comps) keep dropping. Fiscal first-quarter comps fell 3.9% in the period ended on May 3. It doesn't expect them to pick up anytime soon, with management projecting a 4% to 6% drop this year. The company estimates it will earn $0.10 to $0.60 per share in 2025, which might not cover the new $0.50 annual dividend. Kohl's share price performance and lower dividends are clear warning signs to stay away from the stock right now. Before you buy stock in Kohl's, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Kohl's wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $660,821!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $886,880!* Now, it's worth noting Stock Advisor's total average return is 791% — a market-crushing outperformance compared to 174% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Lawrence Rothman, CFA has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. If You'd Invested $5,000 in Kohl's Stock 3 Years Ago, Here's How Much You'd Have Today was originally published by The Motley Fool
Yahoo
30 minutes ago
- Yahoo
Citi initiates coverage on biotech amid improving sentiment in sector
-- Citi initiated coverage on small- and mid-cap biotechnology companies on early signs of improving sentiment in a sector weighed down this year by policy uncertainty and weak investor interest. The brokerage launched with Buy ratings on Acumen, Amylyx, Arcellx, NewAmsterdam Pharma, and Protagonist Therapeutics (NASDAQ:PTGX), and a Sell rating on Novavax (NASDAQ:NVAX). It pointed to deep pipelines and catalysts expected in the second half of 2025 as reasons for optimism in selected stocks despite broader sector underperformance. Biotech shares have lagged the broader market, with the SPDR S&P Biotech (NYSE:XBI) ETF down over 9% year-to-date, while the S&P500 has gained nearly 3%. Citi said persistent concerns around U.S. drug pricing policy have weighed on the group but noted signs of "policy fatigue" among investors and a shift back toward company fundamentals. While large-cap biopharma names such as Eli Lilly (NYSE:LLY), Vertex (NASDAQ:VRTX) and Gilead (NASDAQ:GILD) have led recent gains, Citi said small- and mid-cap stocks may begin to benefit if sentiment continues to recover. Recent deal activity and partnerships suggest a pickup in business development interest, and expectations of a U.S. interest rate cut in September could support further momentum, it added. Citi emphasized the potential of U.S.-based biotechs in areas such as immunology, cardiology, oncology, and rare neurological diseases. It cautioned against companies focused on respiratory vaccines, citing seasonality and political risk. Related articles Citi initiates coverage on biotech amid improving sentiment in sector MS starts coverage of at Equal-Weight on balanced risk-reward Caterpillar's E&T segment is likely a core driver to the next EPS cycle: BofA Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
30 minutes ago
- Yahoo
Zacks Industry Outlook Highlights CVS Health, BrightSpring Health Services and GeneDx
Chicago, IL – June 17, 2025 – Today, Zacks Equity Research discusses CVS Health CVS, BrightSpring Health Services, Inc. BTSG and GeneDx Holdings Corp. WGS. Link: The Medical Services sector is experiencing significant transformation fueled by advancements in technology, increased adoption of value-based care and focus on patient-centric solutions and precision medicine. Rising demand for remote treatment is accelerating digital healthcare growth, especially in telemedicine and AI-powered analytics. Providers are using these tools to improve diagnostics, streamline operations, and enhance outcomes, while value-based models promote preventive and personalized care. According to a Precedence Research report, the global healthcare analytics market was valued at $53.1 billion in 2024 and is projected to witness a CAGR of 21.4% from 2025 to 2034, benefiting payers, professionals, and patients with advanced insights and services. Stocks like CVS Health, BrightSpring Health Services, Inc. and GeneDx Holdings Corp. are poised to benefit from this shift. Meanwhile, as the U.S. healthcare system faces post-pandemic pressure, shifting payer mix and labor shortages, demand for skilled nursing professionals is surging. A 2024 Mercer report projects a shortfall of over 100,000 healthcare workers by 2028, including 73,000 nursing assistants. This will elevate labor costs, though tech-driven care models are driving new, specialized roles. The Zacks Medical Services industry comprises third-party service providers and caregivers appointed by core healthcare companies for economies of scale. The industry includes pharmacy benefit managers, contract research organizations, wireless MedTech companies, third-party testing labs, surgical facility providers and healthcare workforce solution providers, among others. Over the years, this industry has strategically moved from volume-based to value-based care. The resurgence in medical tourism is further boosting the sector. This changing pattern of care calls for advanced facilities, thus increasing the need to appoint specialized external service providers. With the growing importance of effective healthcare management, the medical service industry has become an integral part of the modern healthcare system. The adoption of digital platforms within the medical device space is gaining prominence in the United States. A 2024 digital health market report by Statista suggests that this market will witness a 9.2% CAGR from 2024 to 2028. The increasing availability of unstructured health data, advanced analytics and the demand for personalized medical services underscore the growing importance of big data in healthcare. According to a Roots Analysis report, the global big data in healthcare market size is estimated to increase from $78 billion in 2024 to $540 billion by 2035, representing a CAGR of 19.20%. Other reports suggest that companies that adopted artificial intelligence technologies witnessed a 50% reduction in treatment costs and experienced more than 50% improvement in patient outcomes. : The lingering impact of COVID-19 as a global health emergency has driven many frontline workers to exit the field. Added to this, a drastic increase in the aging population in recent times (about 10,000 individuals aged 59-77 are joining Medicare plans daily) has made the healthcare staffing shortage more pronounced. According to McKinsey, while the global economy could generate 40 million new healthcare jobs by 2030, a significant gap remains. WHO projects a shortfall of 9.9 million physicians, nurses, and midwives worldwide over the same period, highlighting the urgent need for workforce expansion in health systems. Needless to say, this supply shortage has led to a significant rise in healthcare wages. Going by an HR for Health report, increased labor costs and staffing challenges have resulted in a rise in hospital expenses. Hospitals have experienced a 15.6% increase in labor expenses per adjusted discharge compared to pre-pandemic levels. : In 2025, the role of nurses continues to evolve with advancements in medical technologies and shifts in healthcare delivery models. Telehealth and remote patient monitoring have expanded nurses' reach beyond traditional hospital settings, enabling them to provide care in rural or underserved areas. Specialized nursing roles, such as nurse practitioners, critical care specialists and geriatric nurses, are in high demand due to the growing complexity of patient needs. Going by the Bureau of Labor Statistics, the overall employment of nurse anesthetists, nurse midwives and nurse practitioners is projected to grow 40% from 2023 to 2033, much faster than the average for all occupations. About 31,900 openings for nurse anesthetists, nurse midwives and nurse practitioners are projected each year, on average, over the decade. The Zacks Medical Services industry falls within the broader Zacks Medical sector. It carries a Zacks Industry Rank #67, which places it in the top 27% of 245 Zacks industries. The group's Zacks Industry Rank, which is basically the average of the Zacks Rank of all the member stocks, indicates flourishing near-term prospects. Our research shows that the top 50% of the Zacks-ranked industries outperforms the bottom 50% by a factor of more than 2 to 1. We will present a few stocks that have the potential to outperform the market based on a strong earnings outlook. But it's worth taking a look at the industry's shareholder returns and current valuation first. The Medical Services Industry has underperformed its sector and the S&P 500 over the past year. The stocks in this industry have collectively lost 13.4% during the said time frame compared with the Medical sector's 12% dip and the S&P 500 composite's surge of 10.6%. On the basis of forward 12-month price-to-earnings (P/E), which is commonly used for valuing medical stocks, the industry is currently trading at 14.6X compared with the S&P 500's 21.9X and the sector's 19.3X. Over the last five years, the industry has traded as high as 20.12X, as low as 13.4X, and at the median of 14.6X. Below, we present three stocks from the Medical Services industry that have been witnessing positive earnings estimate revisions and carry a Zacks Rank #1 (Strong Buy) or #2 (Buy) at present. You can see the complete list of today's Zacks #1 Rank stocks here. GeneDx: This genomics company provides genetic testing services. It primarily offers pediatric and rare disease diagnostics with a focus on whole-exome and genome sequencing, as well as data and information services. The company is also developing an AI-based platform for NGS analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. This Zacks Rank #1 stock's 2025 expected earnings growth rate is 336%. The Zacks Consensus Estimate for WGS' 2025 revenues indicates a rise of 22.5% from 2024. CVS: It is a pharmacy innovation company with integrated offerings across the entire spectrum of pharmacy care. CVS Health is investing in advanced technological capabilities to cut down costs and improve customer experience. Improved Medicare Advantage star ratings for the 2025 payment year are a positive development for the company. CVS Health's 2025 and 2026 earnings growth rates are pegged at 12.6% and 14.3%, respectively. CVS has a long-term expected earnings growth rate of 11.4%. The stock holds a Zacks Rank #2 currently. BrightSpring: The company operates as a home and community-based healthcare services platform in the United States. BrightSpring is delivering significant improvements in care quality across its diversified service portfolio, boosting stakeholders' and investors' sentiment. In Home Health, over 80% of branches are now rated 4 stars or higher, with the 60-day hospitalization rate continuing to decline. BrightSpring's 2025 expected earnings growth rate is 82.1%. The Zacks Consensus Estimate for BTSG's 2025 revenues indicates a rise of 9.1% over 2024. The stock carries a Zacks Rank #2 at present. Why Haven't You Looked at Zacks' Top Stocks? Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year. Today you can access their live picks without cost or obligation. See Stocks Free >> Join us on Facebook: Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Media Contact Zacks Investment Research 800-767-3771 ext. 9339 support@ Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CVS Health Corporation (CVS) : Free Stock Analysis Report GeneDx Holdings Corp. (WGS) : Free Stock Analysis Report BrightSpring Health Services, Inc. (BTSG) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
